DK3253795T3 - Hidtil ukendte bindende proteiner, der omfatter et ubiquitin-mutein, og antistoffer eller antistoffragmenter - Google Patents

Hidtil ukendte bindende proteiner, der omfatter et ubiquitin-mutein, og antistoffer eller antistoffragmenter

Info

Publication number
DK3253795T3
DK3253795T3 DK16702746.5T DK16702746T DK3253795T3 DK 3253795 T3 DK3253795 T3 DK 3253795T3 DK 16702746 T DK16702746 T DK 16702746T DK 3253795 T3 DK3253795 T3 DK 3253795T3
Authority
DK
Denmark
Prior art keywords
antibodies
antibody fragments
binding proteins
proteins containing
unknown binding
Prior art date
Application number
DK16702746.5T
Other languages
English (en)
Inventor
Eva Bosse-Doenecke
Mathias Kahl
Florian Settele
Paul Knick
Markus Liebscher
Erik Fiedler
Julia Hennicke
Original Assignee
Navigo Proteins Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navigo Proteins Gmbh filed Critical Navigo Proteins Gmbh
Application granted granted Critical
Publication of DK3253795T3 publication Critical patent/DK3253795T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
DK16702746.5T 2015-02-06 2016-02-04 Hidtil ukendte bindende proteiner, der omfatter et ubiquitin-mutein, og antistoffer eller antistoffragmenter DK3253795T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15154150 2015-02-06
EP15169863 2015-05-29
PCT/EP2016/052345 WO2016124670A1 (en) 2015-02-06 2016-02-04 Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments

Publications (1)

Publication Number Publication Date
DK3253795T3 true DK3253795T3 (da) 2019-07-29

Family

ID=55299485

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16702746.5T DK3253795T3 (da) 2015-02-06 2016-02-04 Hidtil ukendte bindende proteiner, der omfatter et ubiquitin-mutein, og antistoffer eller antistoffragmenter

Country Status (4)

Country Link
US (2) US20180030140A1 (da)
EP (1) EP3253795B1 (da)
DK (1) DK3253795T3 (da)
WO (1) WO2016124670A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
JP6856938B2 (ja) 2015-07-16 2021-04-14 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規な免疫グロブリン結合タンパク質およびアフィニティ精製におけるそれらの使用
DK3325514T3 (da) * 2015-07-20 2019-12-16 Navigo Proteins Gmbh Her2-bindende proteiner baseret på di-ubiquitin-muteiner
WO2017013136A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
US11813336B2 (en) 2016-05-04 2023-11-14 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
CN109963864B (zh) 2016-08-11 2024-01-02 瑞普利金公司 用于亲和色谱的碱性稳定性fc结合蛋白
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
WO2018120842A1 (zh) * 2016-12-30 2018-07-05 上海欣百诺生物科技有限公司 一种双功能分子及其应用
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
JP2021508479A (ja) * 2017-12-27 2021-03-11 テネオバイオ， インコーポレイテッド ヘテロ二量体特異的抗体上のｃｄ３デルタ及びｃｄ３イプシロン
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
CN110887967B (zh) * 2018-09-10 2023-06-02 中国科学院苏州纳米技术与纳米仿生研究所 一种检测抗体结合能力的方法及其应用
CN110887961A (zh) * 2018-09-10 2020-03-17 中国科学院苏州纳米技术与纳米仿生研究所 一种用于抗体筛选的固相载体及试剂盒
MX2021007283A (es) 2018-12-18 2021-07-15 Navigo Proteins Gmbh Proteinas de union especificas del folr1 novedosas para diagnostico y tratamiento del cancer.
CA3136229A1 (en) * 2019-04-10 2020-10-15 Navigo Proteins Gmbh Novel psma specific binding proteins for cancer diagnosis and treatment
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
EP4161954B1 (en) * 2020-07-16 2023-11-01 Navigo Proteins Gmbh Serum stable binding proteins for human her2 for theranostic applications
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
WO2022223790A1 (en) * 2021-04-23 2022-10-27 Navigo Proteins Gmbh Novel human programmed death ligand 1 (pd-l1) specific binding molecules
KR20250090347A (ko) * 2022-10-24 2025-06-19 나피고 프로타인스 게엠베하 프로그램화 사멸 리간드 1 (pd-l1)에 대한 높은 결합 친화도를 갖는 신규한 단백질

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563869B2 (en) * 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
RU2553333C2 (ru) 2009-12-14 2015-06-10 Сцил Протеинс Гмбх Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами
CA2837804C (en) 2011-06-15 2018-03-20 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
EP2727942A1 (en) * 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
KR102236367B1 (ko) * 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질

Also Published As

Publication number Publication date
US20190292266A1 (en) 2019-09-26
EP3253795A1 (en) 2017-12-13
EP3253795B1 (en) 2019-04-17
US20180030140A1 (en) 2018-02-01
WO2016124670A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
DK3253795T3 (da) Hidtil ukendte bindende proteiner, der omfatter et ubiquitin-mutein, og antistoffer eller antistoffragmenter
PL3461261T3 (pl) Białka wiążące jednołańcuchowy fragment zmienny CD3
IL281783A (en) Sirpα binding proteins and methods of use thereof
DK3638698T3 (da) Anti-TMPRSS2-antistoffer og antigenbindingsfragmenter
DK3356413T3 (da) Anti-tigit-antigenbindingsproteiner og fremgangsmåder til anvendelse deraf
DK3476399T3 (da) Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf
DK3182999T3 (da) Anti-lag3-antistoffer og antigenbindingsfragmenter
IL262437A (en) Bispecific binding proteins and uses thereof
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
DK3390444T3 (da) Anti-tl1a-antigenbindende proteiner og anvendelser deraf
DK3347379T5 (da) Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf
DK3176181T3 (da) Anti-ctla4 monoklonal antistof eller antigenbindende fragment deraf, medicinal sammensætning og anvendelse
DK3922645T3 (da) Anti-pro/latent-myostatin-antistoffer og anvendelse heraf
IL274891A (en) Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
DK3368555T3 (da) Dobbeltfunktionsproteiner og farmaceutisk sammensætning omfattende disse
LT3247725T (lt) Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123
IL258448A (en) Antigen-binding proteins that activate the leptin receptor
DK3275895T3 (da) Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
DK3455261T3 (da) Anti-ror2-antistoffer, antistoffragmenter, immunkonjugater deraf og anvendelser deraf
IL286929A (en) Trispecific binding proteins, methods, and uses thereof
MA42613A (fr) Filtration en profondeur chargée de protéines de liaison à un antigène
DK3290441T3 (da) Rgma-bindingsprotein og anvendelse deraf
IL266426B (en) Antigen-binding proteins that antagonize leptin receptor
DK3331553T3 (da) Hidtil ukendte, antihumane gpvi-antistoffer og anvendelser deraf